Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref.
studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results deaths Eclinical improvement Edeath or ventilation E

COVID 19 hospitalized meta-analysis

GLUCOCOVID, 2020 RCTcorticosteroidscontrolCOVID 19 hospitalizedhigh
34/29 suggested
Metcovid, 2020
  NCT04343729		 RCTmethylprednisoloneplaceboCOVID 19 hospitalizedsome concern
209/207 inconclusive -7%
RECOVERY dexamethasone, 2020
  NCT04381936		 RCTdexamethasonestandard of careCOVID 19 hospitalizedsome concern
2104/4321 conclusif demonstrated-15%
Fernández Cruz, 2020 OBScorticosteroidsstandard of careCOVID 19 hospitalizedserious
396/67 suggested -59%

COVID-19 severe or critically meta-analysis

CAPE-COVID, 2020
  NCT02517489		 RCTHydrocortisoneplaceboCOVID-19 severe or criticallylow
76/73 inconclusive -26%
COALITION II (Furtado), 2020
  NCT04321278		 RCTHydrocortisonehydroxychloroquineCOVID-19 severe or criticallysome concern
214/183 inconclusive 7%
CODEX (Tomazini), 2020
  NCT04327401		 RCTdexamethasonestandard of careCOVID-19 severe or criticallysome concern
151/148 inconclusive -3%
Edalatifard, 2020
  IRCT20200404046947N1		 RCTmethylprednisolonestandard of careCOVID-19 severe or criticallyhigh
34/34 conclusif demonstrated-64%
REMAP-CAP, fixed 7-day course, 2020
  NCT02735707		 RCTHydrocortisonestandard of careCOVID-19 severe or criticallysome concern
143/108 inconclusive -5% 26% 157%
REMAP-CAP, shock-dependent course, 2020
  NCT02735707		 RCTcorticosteroidsstandard of careCOVID-19 severe or criticallysome concern
152/108 inconclusive -2% 3%
Jianfeng, 2020 OBScorticosteroidsstandard of careCOVID-19 severe or criticallyserious
-/- safety concern 165%
Raef, 2020 OBScorticosteroidsstandard of careCOVID-19 severe or criticallycritical
-/- suggested -50%
Lu, 2020 OBScorticosteroidscontrolCOVID-19 severe or criticallyserious
151/93 inconclusive 206%

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

 

- About us - Contact us - Method Made with in Lyon - Credits - Privacy policy - Licence Creative Commons